QQQ   348.30 (-0.48%)
AAPL   178.91 (+0.91%)
MSFT   330.28 (-0.28%)
META   263.57 (+0.40%)
GOOGL   123.36 (-0.25%)
AMZN   120.28 (-1.13%)
TSLA   199.58 (-0.79%)
NVDA   384.26 (-4.20%)
NIO   7.43 (+0.27%)
BABA   79.61 (+1.19%)
AMD   118.79 (-5.17%)
T   15.76 (+0.77%)
F   11.99 (-4.77%)
MU   68.43 (-4.55%)
CGC   0.82 (-3.15%)
GE   101.05 (-1.32%)
DIS   87.97 (+0.17%)
AMC   4.51 (-2.59%)
PFE   38.09 (+2.92%)
PYPL   62.04 (-0.02%)
NFLX   394.67 (+0.43%)
QQQ   348.30 (-0.48%)
AAPL   178.91 (+0.91%)
MSFT   330.28 (-0.28%)
META   263.57 (+0.40%)
GOOGL   123.36 (-0.25%)
AMZN   120.28 (-1.13%)
TSLA   199.58 (-0.79%)
NVDA   384.26 (-4.20%)
NIO   7.43 (+0.27%)
BABA   79.61 (+1.19%)
AMD   118.79 (-5.17%)
T   15.76 (+0.77%)
F   11.99 (-4.77%)
MU   68.43 (-4.55%)
CGC   0.82 (-3.15%)
GE   101.05 (-1.32%)
DIS   87.97 (+0.17%)
AMC   4.51 (-2.59%)
PFE   38.09 (+2.92%)
PYPL   62.04 (-0.02%)
NFLX   394.67 (+0.43%)
QQQ   348.30 (-0.48%)
AAPL   178.91 (+0.91%)
MSFT   330.28 (-0.28%)
META   263.57 (+0.40%)
GOOGL   123.36 (-0.25%)
AMZN   120.28 (-1.13%)
TSLA   199.58 (-0.79%)
NVDA   384.26 (-4.20%)
NIO   7.43 (+0.27%)
BABA   79.61 (+1.19%)
AMD   118.79 (-5.17%)
T   15.76 (+0.77%)
F   11.99 (-4.77%)
MU   68.43 (-4.55%)
CGC   0.82 (-3.15%)
GE   101.05 (-1.32%)
DIS   87.97 (+0.17%)
AMC   4.51 (-2.59%)
PFE   38.09 (+2.92%)
PYPL   62.04 (-0.02%)
NFLX   394.67 (+0.43%)
QQQ   348.30 (-0.48%)
AAPL   178.91 (+0.91%)
MSFT   330.28 (-0.28%)
META   263.57 (+0.40%)
GOOGL   123.36 (-0.25%)
AMZN   120.28 (-1.13%)
TSLA   199.58 (-0.79%)
NVDA   384.26 (-4.20%)
NIO   7.43 (+0.27%)
BABA   79.61 (+1.19%)
AMD   118.79 (-5.17%)
T   15.76 (+0.77%)
F   11.99 (-4.77%)
MU   68.43 (-4.55%)
CGC   0.82 (-3.15%)
GE   101.05 (-1.32%)
DIS   87.97 (+0.17%)
AMC   4.51 (-2.59%)
PFE   38.09 (+2.92%)
PYPL   62.04 (-0.02%)
NFLX   394.67 (+0.43%)
NASDAQ:RUBY

Rubius Therapeutics (RUBY) Stock Forecast, Price & News

$0.02
0.00 (-19.13%)
(As of 03:17 PM ET)
Compare
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.01
$1.57
Volume
216,613 shs
Average Volume
2.65 million shs
Market Capitalization
$1.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RUBY stock logo

About Rubius Therapeutics (NASDAQ:RUBY) Stock

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA.

Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Stock News Headlines

Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Former Rubius CEO jumps to another Flagship spinout
Rubius Therapeutics, Inc. (RUBY)
Rubius Therapeutics Inc
Flagship-backed Vesalius lays off 43%
Rubius Therapeutics scraps platform, lays off 160
Rubius Therapeutics Announces Strategic Update
Rubius Therapeutics to Provide Strategic Update
See More Headlines
Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Company Calendar

Last Earnings
11/08/2021
Today
5/31/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RUBY
Fax
N/A
Employees
269
Year Founded
N/A

Profitability

Net Income
$-179,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.17 per share

Miscellaneous

Free Float
85,687,000
Market Cap
$1.66 million
Optionable
Not Optionable
Beta
2.38

Key Executives

  • Craig R. Jalbert
    President, Treasurer, Secretary & Director
  • James Jogerst
    Chief Business Officer
  • Lori Murray
    Chief Corporate Affairs Officer
  • Tamyra A. Toole
    Vice President-Regulatory Affairs













RUBY Stock - Frequently Asked Questions

Should I buy or sell Rubius Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RUBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RUBY, but not buy additional shares or sell existing shares.
View RUBY analyst ratings
or view top-rated stocks.

How have RUBY shares performed in 2023?

Rubius Therapeutics' stock was trading at $0.1750 at the start of the year. Since then, RUBY stock has decreased by 89.5% and is now trading at $0.0184.
View the best growth stocks for 2023 here
.

When is Rubius Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our RUBY earnings forecast
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) released its earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same quarter last year, the business posted ($0.51) earnings per share.

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rubius Therapeutics own?
When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Dannielle Appelhans, David R Epstein, Laurence A Turka, Maiken Keson-Brookes, Pablo J Cagnoni and Ventures Fund Iv Gene Flagship.
View institutional ownership trends
.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $0.02.

How much money does Rubius Therapeutics make?

Rubius Therapeutics (NASDAQ:RUBY) has a market capitalization of $1.66 million. The company earns $-179,670,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis.

How many employees does Rubius Therapeutics have?

The company employs 269 workers across the globe.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The official website for the company is www.rubiustx.com. The company can be reached via phone at (508) 543-1720 or via email at ir@rubiustx.com.

This page (NASDAQ:RUBY) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -